View Future GrowthAion Therapeutic 과거 순이익 실적과거 기준 점검 0/6Aion Therapeutic 의 수입은 연평균 -506%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 10.7%의 비율로 증가했습니다. 매출은 연평균 563.3%의 비율로 증가해 왔습니다.핵심 정보-506.02%순이익 성장률-163.65%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률563.34%자기자본이익률n/a순이익률-451.18%최근 순이익 업데이트31 Jan 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.공고 • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.공고 • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.공고 • Oct 24Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction.Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction on October 10, 2023. The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of AION, to be issued at a deemed price of CAD 0.05 per share. AION may also be required to pay contingent consideration of $2,000,000 (CAD 2.74 million) if Toppen achieves revenue equal to or greater than $5,000,000 (CAD 6.84 million) for the period from October 18, 2023 to April 30, 2025. The completion of the Proposed Acquisition is subject to the successful completion of the Company’s due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. The completion of the Proposed Acquisition is currently expected to occur by the end of 2023.공고 • Oct 06Aion Therapeutic Inc. announced that it has received CAD 0.6425 million in fundingOn October 5, 2023, Aion Therapeutic Inc. closed the transaction. The company has issued 21,500,000 units at a price of CAD 0.01 per unit, for gross proceeds of CAD 215,000 in its second tranche closing. Including the first tranche of the unit offering, the company has issued a total of 64,250,000 units for total gross proceeds of CAD 642,500 in the transaction.공고 • Aug 15Aion Therapeutic Inc. announced that it has received CAD 0.4275 million in fundingOn August 14, 2023, Aion Therapeutic Inc. closed the transaction. The company issued 42,750,000 units at an issue price of CAD 0.01 per unit for the gross proceeds of CAD 427,500. Each Unit consists of one common share and one half of one common share purchase warrant. Each full Warrant is exercisable to acquire one Share for a period of eighteen months following the closing of the Unit Offering at an exercise price of CAD 0.10 per Warrant Share. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.공고 • Jul 07Aion Therapeutic Announces Resignation of Rosy Mondin as DirectorAion Therapeutic Inc. announced that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company.공고 • Jul 06Aion Therapeutic Inc. announced that it expects to receive CAD 0.5 million in fundingAion Therapeutic Inc announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.01 per share for gross proceeds of up to CAD 500,000 on July 4, 2023. Each unit consisting of one common share and one-half of one common share purchase warrant. Each full warrant will be exercisable to acquire one share for a period of 18 months following the closing of the unit offering at an exercise price of CAD 0.1 per warrant share. The transaction is expected to close on or about July 31, 2023.매출 및 비용 세부 내역Aion Therapeutic가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:ANTC.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Jan 251-72031 Oct 241-72031 Jul 241-62030 Apr 240-61031 Jan 240-11031 Oct 230-11031 Jul 230-11030 Apr 23001031 Jan 230-21031 Oct 220-21031 Jul 220-31130 Apr 220-41131 Jan 220-72131 Oct 210-82031 Jul 210-82030 Apr 210-82031 Jan 210-32031 Oct 200-21031 Jul 200-11030 Apr 200-11031 Jan 200-11031 Oct 190-11031 Jul 190-52030 Apr 190-51031 Jan 190-630양질의 수익: ANTC.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: ANTC.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 ANTC.F의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ANTC.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ANTC.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ANTC.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/19 08:29종가2026/05/29 00:00수익2025/01/31연간 수익2024/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aion Therapeutic Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.
공고 • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.
공고 • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.
공고 • Oct 24Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction.Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction on October 10, 2023. The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of AION, to be issued at a deemed price of CAD 0.05 per share. AION may also be required to pay contingent consideration of $2,000,000 (CAD 2.74 million) if Toppen achieves revenue equal to or greater than $5,000,000 (CAD 6.84 million) for the period from October 18, 2023 to April 30, 2025. The completion of the Proposed Acquisition is subject to the successful completion of the Company’s due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. The completion of the Proposed Acquisition is currently expected to occur by the end of 2023.
공고 • Oct 06Aion Therapeutic Inc. announced that it has received CAD 0.6425 million in fundingOn October 5, 2023, Aion Therapeutic Inc. closed the transaction. The company has issued 21,500,000 units at a price of CAD 0.01 per unit, for gross proceeds of CAD 215,000 in its second tranche closing. Including the first tranche of the unit offering, the company has issued a total of 64,250,000 units for total gross proceeds of CAD 642,500 in the transaction.
공고 • Aug 15Aion Therapeutic Inc. announced that it has received CAD 0.4275 million in fundingOn August 14, 2023, Aion Therapeutic Inc. closed the transaction. The company issued 42,750,000 units at an issue price of CAD 0.01 per unit for the gross proceeds of CAD 427,500. Each Unit consists of one common share and one half of one common share purchase warrant. Each full Warrant is exercisable to acquire one Share for a period of eighteen months following the closing of the Unit Offering at an exercise price of CAD 0.10 per Warrant Share. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.
공고 • Jul 07Aion Therapeutic Announces Resignation of Rosy Mondin as DirectorAion Therapeutic Inc. announced that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company.
공고 • Jul 06Aion Therapeutic Inc. announced that it expects to receive CAD 0.5 million in fundingAion Therapeutic Inc announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.01 per share for gross proceeds of up to CAD 500,000 on July 4, 2023. Each unit consisting of one common share and one-half of one common share purchase warrant. Each full warrant will be exercisable to acquire one share for a period of 18 months following the closing of the unit offering at an exercise price of CAD 0.1 per warrant share. The transaction is expected to close on or about July 31, 2023.